Glucose metabolism impairment in Parkinson's disease

作者全名："Dai, Chengcheng; Tan, Changhong; Zhao, Lili; Liang, Yi; Liu, Guohui; Liu, Hang; Zhong, Yuke; Liu, Zhihui; Mo, Lijuan; Liu, Xi; Chen, Lifen"

作者地址："[Dai, Chengcheng; Tan, Changhong; Zhao, Lili; Liang, Yi; Liu, Guohui; Liu, Hang; Zhong, Yuke; Liu, Zhihui; Mo, Lijuan; Liu, Xi; Chen, Lifen] Chongqing Med Univ, Affiliated Hosp 2, Dept Neurol, 74 Linjiang Rd, Chongqing 400010, Peoples R China; [Liu, Xi; Chen, Lifen] 74 Linjiang Rd, Chongqing 400010, Peoples R China"

通信作者："Liu, X; Chen, LF (通讯作者)，74 Linjiang Rd, Chongqing 400010, Peoples R China."

来源：BRAIN RESEARCH BULLETIN

ESI学科分类：NEUROSCIENCE & BEHAVIOR

WOS号：WOS:001007184900001

JCR分区：Q2

影响因子：3.5

年份：2023

卷号：199

期号：　

开始页：　

结束页：　

文献类型：Review

关键词：Parkinson's disease; Glucose metabolism impairment; Pathophysiological mechanism; Energy supply insufficiency; Therapy

摘要："Impairments in systematic and regional glucose metabolism exist in patients with Parkinson's disease (PD) at every stage of the disease course, and such impairments are associated with the incidence, progression, and special phenotypes of PD, which affect each physiological process of glucose metabolism including glucose uptake, glycolysis, tricarboxylic acid cycle, oxidative phosphorylation, and pentose phosphate shunt pathway. These impairments may be attributed to various mechanisms, such as insulin resistance, oxidative stress, abnormal glycated modification, blood-brain-barrier dysfunction, and hyperglycemia-induced damages. These mechanisms could subsequently cause excessive methylglyoxal and reactive oxygen species production, neuro-inflammation, abnormal aggregation of protein, mitochondrial dysfunction, and decreased dopamine, and finally result in energy supply insufficiency, neurotransmitter dysregulation, aggregation and phosphorylation of alpha-synuclein, and dopaminergic neuron loss. This review discusses the glucose metabolism impairment in PD and its pathophysiological mechanisms, and briefly summarized the currently-available therapies targeting glucose metabolism impairment in PD, including glucagon-likepeptide-1 (GLP-1) receptor agonists and dual GLP-1/ gastric inhibitory peptide receptor agonists, metformin, and thiazoledinediones."

基金机构：National Natural Science Foundation of China [82001367]; Natural Science Foundation of Chongqing [cstc2021jcyj-msxmX0180]; Kuanren Talent Program of The Second Affiliated Hospital of Chongqing Medical University

基金资助正文："This study is supported by National Natural Science Foundation of China (grant number: 82001367, receiver: Xi Liu) , Natural Science Foundation of Chongqing (grant number: cstc2021jcyj-msxmX0180, receiver: Xi Liu) , and Kuanren Talent Program of The Second Affiliated Hospital of Chongqing Medical University (receiver: Xi Liu) ."